Alpha 2.0
Login Register
» Authors » Paul Koller

Paul Koller

Explore the profile of Paul Koller including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 40
Citations 115
Followers 0
Related Specialties
Hematology
Oncology
General Surgery
Top 10 Co-Authors
Guido Marcucci
Amandeep Salhotra
Ibrahim Aldoss
Vinod Pullarkat
Haris Ali
Ryotaro Nakamura
Ahmed Aribi
Anthony Stein
Hoda Pourhassan
Stephen J Forman
Published In
Bone Marrow Transplant
Leuk Lymphoma
Transplant Cell Ther
Am J Hematol
Br J Haematol
Affiliations
Soon will be listed here.
Recent Articles
1.
Impact of hyperhydration on fluid overload and hematopoietic cell transplant after post-transplant cyclophosphamide-based graft-versus-host-disease prophylaxis
Samuels D, Yao J, Samara Y, Yang D, Mokhtari S, Tiemann K, et al.
Front Immunol . 2025 Mar; 16:1543099. PMID: 40051639
Introduction: Hemorrhagic cystitis (HC) is an early complication after hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy). Hyperhydration can reduce HC, but may lead to fluid overload (FO), which has...
2.
Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease
Blackmon A, Afkhami M, Yang D, Mokhtari S, Samara Y, Pourhassan H, et al.
Bone Marrow Transplant . 2024 Dec; 60(2):165-174. PMID: 39695333
Patients with AML and measurable residual disease (MRD) undergoing allogeneic hematopoietic cell transplantation (HCT) may benefit from myeloablative conditioning (MAC) when feasible to reduce relapse risk. Fludarabine-Melphalan (FluMel) is a...
3.
Combined Cytokine Blockade Therapy (CCBT) Using Basiliximab and Infliximab for Treatment of Steroid-Refractory Graft-Versus-Host Disease (SR-GvHD)
Pourhassan H, Nguyen T, Yang D, Otoukesh S, Arslan S, Blackmon A, et al.
Cancers (Basel) . 2024 Dec; 16(23). PMID: 39682101
Background: The standard first-line treatment for acute graft-versus-host disease (aGvHD) is systemic, high-dose glucocorticoids which have historically had limited responses. Combined cytokine blockade therapy (CCBT) with the monoclonal antibodies infliximab...
4.
Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia
Aldoss I, Zhang J, Shimamoto K, Saygin C, Robbins M, Agrawal V, et al.
Haematologica . 2024 Nov; PMID: 39506897
BCL-2 protein overexpression, common in B-cell acute lymphoblastic leukemia (B-ALL), including the Philadelphia (Ph)-like subtype, mediates leukemic cell survival. We treated 24 patients with 14 days of BCL-2 inhibitor, venetoclax,...
5.
Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes
Tinajero J, Xu S, Ngo D, Li S, Palmer J, Nguyen T, et al.
Br J Haematol . 2024 Nov; 206(3):868-875. PMID: 39505575
Pegaspargase is a key drug for the treatment of younger adults with acute lymphoblastic leukaemia (ALL). Pegaspargase-associated hepatotoxicity is most common during induction, and its incidence increases with age and...
6.
Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic phase: the ASC2ESCALATE Phase II trial
Atallah E, Mauro M, Sasaki K, Levy M, Koller P, Yang D, et al.
Future Oncol . 2024 Oct; 20(38):3065-3075. PMID: 39387441
Up to 40% of newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML-CP) discontinue treatment by 5 years, primarily due to resistance or intolerance. Rates of resistance to...
7.
Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation
Desai A, Samara Y, Yang D, Ball B, Braun A, Koller P, et al.
Leuk Res . 2024 Aug; 145:107565. PMID: 39208597
Introduction: Allogeneic Hematopoietic cell transplantation (allo-HCT) remains the only curative therapy for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The impact of spliceosome mutations on allo-HCT outcome is unclear...
8.
The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia
Ngo D, Tinajero J, Song J, Ma H, Quirk E, Koller P, et al.
Leuk Lymphoma . 2024 Aug; 65(13):2016-2024. PMID: 39155594
Reactive pleocytosis in the CSF has been observed with blinatumomab but has not been well-described. We performed a retrospective study of 88 patients who received intrathecal chemotherapy (IT) while on...
9.
Concurrent versus sequential or no triazole anti-fungal therapy in patients undergoing 7 + 3 plus midostaurin induction for FLT-3 acute myelogenous leukemia
Ngo D, Tinajero J, Zhang J, Stein A, Marcucci G, Salhotra A, et al.
J Oncol Pharm Pract . 2024 Aug; :10781552241276547. PMID: 39150342
Introduction: Midostaurin is a multikinase inhibitor approved for the treatment of adult patients with newly diagnosed FMS-like tyrosine kinase 3 mutated (FLT3m) acute myeloid leukemia (AML). Azole antifungal medications are...
10.
Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings
Otoukesh S, Yang D, Mokhtari S, Pourhassan H, Agrawal V, Arslan S, et al.
Bone Marrow Transplant . 2024 Aug; 59(11):1542-1551. PMID: 39147891
The optimal myeloablative conditioning regimen for ALL patients undergoing hematopoietic cell transplant (HCT) with an alternative donor is unknown. We analyzed HCT outcomes ALL patients (n = 269) who underwent...